Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Sepsis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04533256

Enrollment

Registered

2020-08-31

Start date

2016-07-10

Completion date

2021-07-30

Last updated

2021-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

organ failure, renal replacement therapy, hemoadsorption

Brief summary

Hemoadsorption has been demonstrated to improve clinical and paraclinical results in critically ill patients with sepsis and septic shock. The present study investigates the effects of three consecutive sessions of hemoadsorption, performed in accordance to the local protocol for treating patients with sepsis, on organ failure, severity scores and 30-days mortality. Paraclinical results and severity scores were obtained before and after the three consecutive sessions.

Interventions

PROCEDURECytoSorb

three consecutive sessions of hemoadsorption in patients with sepsis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with sepsis or septic shock who require hemoadsorption in accordance with local guidelines

Exclusion criteria

* unsigned informed consent * duration of therapy under 12 hours * death before the three consecutive sessions

Design outcomes

Primary

Measure	Time frame	Description
28-days mortality	28 days after ICU admission	28-days mortality

Secondary

Measure	Time frame	Description
severity score	3 days	dynamics of SOFA score (Sequential Organ Failure Assessment) calculated as the mathematical difference in post-therapy SOFA score and pre-therapy SOFA score

Countries

Romania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026